Groundbreaking Results in Neoadjuvant Efti Therapy for STS
Today, we celebrate a significant advancement in the treatment of soft tissue sarcoma (STS) with the EFTISARC-NEO Phase II trial. Conducted by Immutep Limited (NASDAQ: IMMP; AUST: IMM.AX), this pioneering study highlights the efficacy of eftilagimod alfa (efti) in conjunction with radiotherapy and KEYTRUDA.
Impressive Outcomes in Patient Responses
The Phase II study achieved remarkable results, surpassing previous benchmarks with a median of 51.5% tumor hyalinization and fibrosis among evaluable participants. This rate is astonishingly over three times the results historically seen with standard radiotherapy, which previously reported only 15%. The study included 38 patients who received this innovative combination therapy.
Dr. Katarzyna Kozak, leading the presentation of these findings at a prestigious medical conference, emphasized the significance of these results. The therapy does not only meet but significantly exceeds the primary endpoint set for this trial, offering hope for improved patient outcomes in a notoriously difficult-to-treat category of cancer.
Significance of Early Surrogate Endpoints
Results like these are pivotal since tumor hyalinization and fibrosis are emerging as essential early indicators of treatment success, correlating positively with overall survival and recurrence-free survival rates in STS patients. Such data can drastically change the landscape of neoadjuvant treatment strategies for individuals diagnosed with this type of cancer.
Safety Profile and Tolerability
Beyond efficacy, the study reported a commendable safety profile. Participants exhibited only one instance of grade ?3 toxicity related to the immunotherapeutic approach, supporting the potential for combining efti with existing treatment modalities without significant adverse effects.
Advancing New Therapeutic Options
Immutep’s commitment to understanding and developing novel immunotherapies places it at the forefront of the fight against STS. The high unmet medical need in this area highlights the importance of these findings as they pave the way for new therapeutic options. Marc Voigt, CEO of Immutep, reiterated this need and expressed gratitude towards everyone involved in the trial.
As the incidence of STS is projected to rise, with significant estimates in the United States alone, the urgency to provide effective treatments grows. The 2025 cases are estimated to be around 13,520, resulting in approximately 5,420 deaths, underscoring the dire requirement for innovative therapies that promise better outcomes.
Immutep’s Ongoing Commitment
Continuing its exploration into the potential of efti, the company has multiple trials in progress, including pivotal studies for various solid tumors. The favorable safety profile is a considerable asset, allowing for combinations that include both radiotherapy and chemotherapy, and furthermore, it has garnered Fast Track designation from the FDA in specific indications.
Looking Ahead
With the results from the EFTISARC-NEO trial, Immutep is not just aiming to meet current medical needs but is actively reshaping the future landscape of soft tissue sarcoma treatment. By fostering such innovative therapeutic avenues, the company is showing its commitment to prioritizing patient health.
Frequently Asked Questions
What is the significance of the EFTISARC-NEO trial results?
The trial results demonstrate a significant improvement in tumor hyalinization and fibrosis compared to historical data, suggesting a promising new therapeutic approach for STS.
How many patients participated in the Phase II study?
Thirty-eight patients were enrolled in the study, which evaluated the combination of efti, radiotherapy, and KEYTRUDA.
What does tumor hyalinization indicate?
Tumor hyalinization serves as a surrogate marker for treatment effectiveness and is associated with improved overall survival and recurrence-free survival in STS.
What is Immutep’s role in developing cancer therapies?
Immutep is a late-stage biotechnology company focused on developing novel immunotherapies, particularly leveraging the LAG-3 pathway to enhance immune responses against cancer.
What are the next steps for Immutep following these results?
Immutep will likely continue to investigate the efficacy of efti in various solid tumors and explore additional clinical applications and combinations to improve patient outcomes.
